Abstract

BackgroundMantle Cell Lymphoma (MCL) is a B cell aggressive neoplasia accounting for about the 6% of all lymphomas. The most common molecular marker of clonality in MCL, as in other B lymphoproliferative disorders, is the ImmunoGlobulin Heavy chain (IGH) rearrangement, occurring in B-lymphocytes. The patient-specific IGH rearrangement is extensively used to monitor the Minimal Residual Disease (MRD) after treatment through the standardized Allele-Specific Oligonucleotides Quantitative Polymerase Chain Reaction based technique. Recently, several studies have suggested that the IGH monitoring through deep sequencing techniques can produce not only comparable results to Polymerase Chain Reaction-based methods, but also might overcome the classical technique in terms of feasibility and sensitivity. However, no standard bioinformatics tool is available at the moment for data analysis in this context.ResultsIn this paper we present HashClone, an easy-to-use and reliable bioinformatics tool that provides B-cells clonality assessment and MRD monitoring over time analyzing data from Next-Generation Sequencing (NGS) technique. The HashClone strategy-based is composed of three steps: the first and second steps implement an alignment-free prediction method that identifies a set of putative clones belonging to the repertoire of the patient under study. In the third step the IGH variable region, diversity region, and joining region identification is obtained by the alignment of rearrangements with respect to the international ImMunoGenetics information system database. Moreover, a provided graphical user interface for HashClone execution and clonality visualization over time facilitate the tool use and the results interpretation. The HashClone performance was tested on the NGS data derived from MCL patients to assess the major B-cell clone in the diagnostic samples and to monitor the MRD in the real and artificial follow up samples.ConclusionsOur experiments show that in all the experimental settings, HashClone was able to correctly detect the major B-cell clones and to precisely follow them in several samples showing better accuracy than the state-of-art tool.

Highlights

  • Mantle Cell Lymphoma (MCL) is a B cell aggressive neoplasia accounting for about the 6% of all lymphomas

  • The ImmunoGlobulin Heavy chain (IGH) rearrangement is a unique DNA sequence that is generated during physiological recombination event occurring in pre-B lymphocytes and further modified in the germinal center during somatic hypermutation process [3]

  • Minimal Residual Disease (MRD) monitoring was conducted by ASO Allele-Specific Oligonucleotides quantitative-Polymerase Chain Reaction (PCR) (q-PCR) on 500 ng of genomic DNA (gDNA), using patient specific primers and consensus probes designed on Complementarity-Determining Region 2 (CDR2) sequences, on Third Complementarity-determining region (CDR3) and FR3 IGH regions, respectively [24]

Read more

Summary

Introduction

Mantle Cell Lymphoma (MCL) is a B cell aggressive neoplasia accounting for about the 6% of all lymphomas. Despite the significant therapeutic progresses reached, several patients still relapse and die due to the emergence of resistant new clones Based on these reasons, molecular markers detection at diagnosis and early identification of patients at high risk of relapse during the natural history of the disease are the major objectives of current onco-hematology translational research. Deletions as well as random insertions of nucleotides among the VDJ gene segments of the IGH genes create a huge junctional diversity Such a highly diverse junctional repertoire gives rise to unique fingerprint-like sequences that are different in each healthy B-lymphoid cell (polyclonal), but constant in tumour population (monoclonal) [4] that retains the IGH rearrangement of the B cell giving rise to the tumour clone

Methods
Results
Discussion
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.